Effect of docetaxel combined with chemotherapy on the survival time, serum tumor markers and metastasis related factors in patients with esophageal cancer after operation
10.3760/cma.j.issn.1008-6706.2019.14.010
- VernacularTitle: 多西他赛联合化疗对食管癌术后患者生存期、血清肿瘤标志物及转移相关因子水平的影响
- Author:
Dong HAO
1
Author Information
1. Department of Cardiothoracic Surgery, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046001, China
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Surgical procedures, operative;
Docetaxel;
Antineoplastic combined chemotherapy protocols;
Tumor markers, biological
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(14):1700-1704
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the application effect of docetaxel combined with capecitabine and oxaliplatin (XELOX) chemotherapy in patients with esophageal cancer undergoing radical operation.
Methods:From February 2013 to December 2015, 69 cases of esophageal cancer in Heji Hospital Affiliated to Changzhi Medical College were treated with radical operation, and they were divided into two group according to the random number table.Thirty-four cases in the control group were treated with XELOX chemotherapy, and 35 cases in the observation group were treated with XELOX chemotherapy + docetaxel.The clinical therapeutic effect and the levels of serum tumor markers[carcinoembryonic antigen(CEA) and squamous cell carcinoma associated antigen(SCC)], serum transfer related factors[interleukin-6(IL-6), nitric oxide synthase(NOS), nitric oxide(NO)]before and after treatment of the two groups were observed and compared.The occurrence and life cycle of the two groups were also analyzed.
Results:The control rate of the disease in the observation group was 74.29% (26/35), which was higher than that in the control group [50% (17/34)](χ2=4.332, P<0.05). The serum levels of CEA and SCC in the observation group were lower than those in the control group(t=15.835, 10.872, all P<0.05). The serum levels of IL-6 and NOS in the observation group were lower than those in the control group, and the level of NO was higher than that in the control group(t=12.200, 8.209, 7.460, all P<0.05). There was no statistically significant difference in the incidence of side effects between the observation group and the control group(P>0.05). The median survival time of the observation group was 12.50 months, while that of the control group was 8.70 months, and the difference was statistically significant(P<0.05).
Conclusion:Docetaxel combined with XELOX chemotherapy can prolong the postoperative life cycle of the patients.
